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Abstract: Leptin and adiponectin represent two newly discovered adipose tissue derived hormones 
with  important  roles  in  energy  homeostasis  and  insulin  resistance.  Their  interrelations  with  the 
manifestations of the HIV associated metabolic syndrome and specific somatomorphic changes i.e. fat 
redistribution is reviewed. A synopsis of published studies is presented and the potential role of leptin 
and adiponectin is discussed. We have described an association of the HIV metabolic syndrome with a 
state of reduced insulin sensitivity due to adiponectin deficiency. The  metabolic syndrome is also 
accompanied by leptin deficiency in lipoatrophic subjects and possibly by a leptin resistance state in 
lipohypertrophic  patients.  Adiponectin  and  /  or  leptin  therapy  in  a  manner  similar  to  other  leptin 
deficiency states may assist in the future management of such patients.  
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INTRODUCTION 
 
  Clinicians face the anxiety of HIV-1 patients with 
metabolic  and  morphological  changes  seen  in 
association  with  their  antiretroviral  therapeutic 
regimens regarding potential long-term effects directly 
related  to  their  therapy
[1].  Recent  studies  have 
confirmed  the  association  between  the  HIV 
combination  of  antiretroviral  regimens,  the  metabolic 
syndrome  and  an  increased  risk  for  cardiovascular 
events
[2,3].  Great  uncertainty  continues  to  exist 
regarding  the  definition  as  well  as  the  exact 
pathophysiology of the HIV associated metabolic and 
morphologic  changes.  New  theories  suggesting 
potential mechanisms are published
[4] but there is still 
difficulty  in  understanding  the  full  spectrum  of  the 
clinical  entity
[1,5].  Many  of  the  endpoints  examined 
during  studies  of  the  syndrome  are  shared  by  the 
general  population  and  thus  are  subject  to  multiple 
confounding  from  genetic,  environmental  (including 
toxicity from the antiretrovirals) and other factors not 
specific to the HIV disease. 
  Adipose tissue derived hormones (adipokines) may 
play an important role in the pathogenesis of the HIV 
associated metabolic syndrome and they have been the 
focus of extensive research over the last few years. Two 
adipokines leptin and adiponectin have been the focus 
of the majority of the research efforts. In the current 
report  we  review  available  literature  on  leptin  and 
adiponectin and their association with the development 
of  phenotypic  and/or  metabolic  changes  in  HIV 
infected subjects treated with HAART.  
 
The HIV associated metabolic syndrome: Diabetes, 
glucose intolerance and insulin resistance were the first 
described manifestations
[1,6]. They were soon followed 
by  reports  of  dyslipidemia
[7-11]  and  body  shape 
changes
[1,8,12-15].  The  term  “lipodystrophy”  that  was 
then  used  is  probably  not  inclusive  of  the  entire 
spectrum  of  manifestations.  Hyperlactatemia  and  loss 
of bone mineral density were recognized subsequently, 
but there is uncertainty as to whether they are part of 
the same process. There is still no clear understanding 
of the pathogenesis of all observed changes and a lack 
of  a  uniform  definition  for  the  HIV  associated 
metabolic  syndrome  exists.  Researchers  initially 
believed  that  this  “new”  HIV  metabolic  syndrome 
shares basic pathophysiologic principles with metabolic 
changes seen in healthy populations as they get older
[9]. 
Attempts  to  use  a  common  definition  for 
“lipodystrophy”  have  been  made
[16-20]  but  are  not  yet 
widely accepted.  
 
Adipokines and their physiologic role: Adipose tissue 
with  both  its  adipocyte  and  non  adipocyte  fractions 
represents a major endocrine organ secreting hormones 
and  other  proteins  including  inflammatory  mediators 
such as plasminogen activator inhibitor type 1, TNF-￿, 
IL-6 and hormones involved in insulin sensitivity like 
leptin and adiponectin
[21-27]. All adipose tissue products 
seem  to  contribute  significantly  in  various  metabolic 
processes both at the local and the  systemic level
[21]. 
Additionally  adipocytes  express  numerous  receptors 
enabling them to respond to distant signals from other 
hormonal  systems
[21].  These  include  insulin  and 
androgen receptors. A recent review describes at least Am. J. Infectious Dis., 2 (3): 141-152, 2006 
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19 different secreted proteins and at least 22 receptors 
expressed in adipose tissue
[21]. The metabolic syndrome 
in  non  HIV  patients  is  characterized
  by 
hyperinsulinemia,  type  2  diabetes  mellitus, 
hypertension,
  hyperlipidemia  and  coronary  heart 
disease  and  the  adipose  tissue  seems  to  play  an 
important role in its pathogenesis
[21,28-30]. 
 
Leptin and its physiologic role: Leptin is an adipocyte 
derived  hormone  involved  in
 energy  homeostasis  and 
insulin
  resistance  via  central  effects
  on  the 
hypothalamus  and  peripheral  effects  on  fatty
  acid 
oxidation
[22,31,32].  In  humans,  hypothalamic  pathways 
mediate  the  leptin  effects  in  energy  homeostasis  and 
leptin seems to primarily serve as a signal of sufficient 
energy for the human body
[22]. If an individual starts to 
receive less nutrition and loses weight, leptin levels will 
decrease  and  concomitantly  through  a  mechanism  of 
physiologic  adaptation  appetite  will  be  increased  and 
energy  expenditure  will  decline
[22,33-35].  In  mice 
experiments leptin deficiency has been associated with 
hyperinsulinemia and insulin resistance that is corrected 
by  exogenous  administration  of  leptin  before  the 
development of persistent obesity
[36,37]. However only a 
few  humans  are  similar  to  these  ob/ob  mice;  high 
instead  of  low  leptin  levels  most  often  accompany 
obesity  representing  likely  a  state  of  leptin 
resistance
[22,33,38]. Studies in HIV-1 negative individuals 
have  shown  an  association  berween  higher  fasting 
leptin  levels  and  obesity,  total  and  central  fat
 
accumulation as well as insulin resistance
[39,40]. Leptin 
levels  directly  correlate  to  adipose  tissue  mass 
(subcutaneous  rather  than  visceral  adipose  tissue)  as 
well as nutritional status in humans 
[41-43]. It has been 
recently  shown  by  researchers  in  our  group  that 
increasing fat mass is associated with higher baseline 
leptin levels and endogenous production rates
[44]. In the 
same  work  leptin  clearance  was  decreasing  with 
increased  adiposity  leading  to  higher  leptin  levels  in 
obese subjects and a state of leptin resistance
[44]. Leptin 
is  an  adipose  tissue  product  and  thus  low  fat
  stores 
could  result  in  hypoleptinemia  in  any  patient  with 
lipoatrophy.  A  generalized  loss
  of  subcutaneous  and 
visceral
  fat,  insulin  resistance  and
  hyperlipidemia  is 
characteristic  of  the  rare  congenital  and  acquired 
lipoatrophies seen in humans
[45-47]. Leptin
 replacement 
in subjects with such syndromes has improved
 glycemic 
control  and  lipid  levels  in  a  recently  published 
interventional human study
[48].  
  Leptin  besides  its  effects  on  energy  homeostasis 
has  regulatory  effects  on  other  traditional  endocrine 
systems  such  as  the  hypothalamic-pituitary-gonadal 
axis and in part, the hypothalamic-pituitary-thyroid axis 
especially in starvation-states
[49,50]. In leptin deficiency 
states  there  is  suppression  of  the  thyroid  and  the 
gonadal  axis  which  is  reversed  with  leptin 
supplementation
[49-52].  In  addition  leptin  may  have  a 
regulatory  role  for  the  hypothalamic-pituitary-adrenal 
axis  (HPA).  In  leptin  deficiency  states  there  is  an 
activation  of  the  HPA  axis  with  increased  levels  of 
corticotrophin-releasing  hormone  (CRH)  and 
hypercortisolemia an effect shown in mice experiments 
and  in  vitro  experiments  involving  human 
adrenocortical cells
[21].  
 
Leptin and the HIV associated metabolic syndrome: 
Fasting leptin levels have been shown to correlate well 
with
  total  body  fat  concentrations  in  HIV-infected 
patients
[53-55]. An association between limb fat loss and 
low  leptin  levels  as  well  as  other  metabolic 
abnormalities  in  HIV  patients  has  been  published
[56] 
however other studies failed to show such associations 
likely due to lack of stratification of patients by type of 
lipodystrophic  body  changes
[57,58].  After  careful 
categorization of HIV-1 infected patients attending our 
ID  clinic  in  4  separate  body  habitus  categories 
(lipohypertrophy,  lipoatrophy,  mixed,  normal)
[59],  we 
hypothesized  that  we  will  observe  leptin  deficiency 
resulting  from  decreased  synthesis  and/or  release  of 
leptin  from  adipocytes  in  patients  exhibiting  either 
peripheral  or  generalized  lipoatrophy
[59].  We  found  a 
significant association between leptin levels and
 insulin 
resistance  in  patients
  with  the  various  morphological 
phenotypes
[59].  Mean  leptin  levels  were  lowest  in 
patients  exhibiting  lipoatrophic  body  shape  changes 
when  compared  to  those  of  patients  with 
lipohypertrophy  who  had  the  highest  leptin  levels
[59]. 
Leptin  levels  in  between  the  two  extremes  were 
observed  in  subjects  with  no  body  shape  changes
[59]. 
Hypoleptinemia  was  independently  associated  with 
insulin resistance in patients with lipoatrophy an effect 
not  confounded  by  central  or  peripheral  fat  mass 
indicating a possible role for leptin in the development 
of  metabolic changes in lipoatrophic patients
[59]. This 
finding  generated  the  hypothesis  that  leptin 
administration in leptin deficient HIV positive subjects 
with  lipoatrophy  would  result  in  correction  of  the 
metabolic disturbance i.e. insulin resistance, as a proof 
of  concept  for  its  role  in  causing  the  syndrome
[59]. 
Another  interesting  finding  of  our  study  was  the 
hyperleptinemia  noted  in  HIV  patients  with 
hypertrophy
[59].  This  could  be  attributed  to  excess 
synthesis  and  release  of  leptin  by  the  adipocytes  or 
excess circulating levels of free unbound leptin due to 
resistance at the leptin receptor level
[59].  
  Recently  a  significant  association  between  leptin 
secretion  and  subcutaneous  fat  has  been  reported  in 
studies  of  leptin  pulse  dynamics  in  relation  to  the 
morphologic  changes  in  HIV  patients
[60].  The 
researchers  reported  a  decrease  in  leptin  levels 
following subcutaneous fat decrements after controlling 
for  visceral  fat  quantity
[60].  There  was  no  specific 
relationship discovered with visceral fat however this 
study did not study purely lipoatrophic patients
[60]. Of 
note in the study by our group lipoatrophic subjects had 
the highest percentage of visceral fat
[59]. Future research Am. J. Infectious Dis., 2 (3): 141-152, 2006 
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is  necessary  to  investigate  the  role  of  regional  fat 
changes  in  producing  hypoleptinemia
[60].  Leptin  gene 
expression  and  leptin  production  from  regional  fat 
compartments  could  be  decreased  due  to  fat  loss
[61]. 
Leptin effects may be fat type specific. Adipose tissue 
lacking  leptin  is  unable  to  correct  the  metabolic 
abnormalities  associated  with  lipoatrophy  when 
transplanted
[62]  to  mice  as  opposed  to  adipose  tissue 
producing leptin i.e. subcutaneous fat
[63]. Leptin exerts 
several  other  important  actions
[64,65]  that  need  to  be 
further explored in HIV subjects. 
 
Adiponectin and its physiological role: Adiponectin 
is  a  newly  appreciated  hormone  discovered  10  years 
ago  and  exclusively  produced  from  mature 
adipocytes
[66-69]. Adiponectin has a collagen like and a 
globular  like  domain  and  has  tertiary  structural 
similarities  with  an  important  inflammatory  cytokine, 
tumor necrosis factor alpha (TNFa)
[66-70]. Adiponectin 
has  been  found  to  be  inversely  associated  with 
components of the metabolic syndrome such as obesity, 
insulin resistance and type II diabetes
[71-74], as well as 
rare forms of congenital and acquired lipodystrophies in 
non-HIV  infected  patients
[75].  Adiponectin  effects  not 
only  depend  on  the  circulating  concentrations  of  the 
hormone  but  also  on  the  expression  of  recently 
identified  specific  receptors  at  the  muscle  (adipoR1) 
and/or  the  liver  (adipoR2)
[76].  Adiponectin  has  a 
beneficial  effect  on  insulin  resistance  which  can  be 
explained by two main mechanisms. First, adiponectin 
mediates an overall decrease of triglycerides in muscle 
and liver by up-regulating the expression of molecules 
involved  in  fatty  acid  oxidation  and  muscle  energy 
expenditure.  This  has  been  demonstrated  in 
experiments  involving  obese  mice 
[77].  Second, 
adiponectin  inhibits  gluconeogenesis  at  the  liver
[78,79]. 
Decreased levels of both leptin and adiponectin  have 
been  seen  in  animal  models  of  lipoatrophy  where 
transgenic overexpression or administration of one of 
the  two  partially  corrected  insulin  resistance  while 
administration of both hormones resulted in complete 
reversal  of  the  insulin  resistance  state
[80,81].  Recent 
studies  have  shown  that  adiponectin  expression  is 
higher in subcutaneous than visceral fat in humans
[41].  
 
Adiponectin  and  the  HIV  associated  metabolic 
syndrome:  In  further  studies  of  HIV  patients  with 
“lipodystrophy”  followed  at  our  institution  we  found 
that adiponectin levels were significantly lower in the 
patients  exhibiting  fat  redistribution  changes
[82].  This 
association was independent of age, leptin levels, HIV 
medication  and  severity  of  disease
[82].  Adiponectin 
levels  were  significantly  associated  with  both 
abdominal  visceral  fat  and  extremity  fat
[82].  Since 
adiponectin expression is higher in subcutaneous than 
visceral fat in humans
[41] visceral fat accumulation and 
subcutaneous  fat  loss  may  lead  to  decreased 
adiponectin  production  both  in  lipoatrophy  and 
lipohypertrophy  subjects.  This  adiponectin  deficiency 
becomes more prominent with peripheral fat loss and 
thus  loss  of  another  adiponectin  supply.  Thus,  fat 
redistribution  may  actually  be  responsible  for  the 
decreased  adiponectin  levels  in  HIV  patients  with
 
mixed  fat  redistribution  phenotypes
[82].  Further 
confirming this hypothesis we found an inverse relation 
between adiponectin levels and abdominal visceral fat 
mass,  serum  triglycerides  and  insulin
  resistance
[82]. 
These findings are consistent with the role of visceral 
adiposity
 in the development of insulin resistance and 
lipid  abnormalities  associated
  with  the  metabolic 
syndrome
[83-86].  Subsequent  studies  confirmed  our 
results  showing  an  association  between  adiponectin 
levels  and  insulin  sensitivity  in  HIV  positive 
subjects
[55,87,88]. Reduced circulating adiponectin levels 
were  reported  in  patients  with  chronic  HIV  infection 
and  fat  redistribution  compared  with  age-  and  body 
mass index-matched HIV-infected patients without fat 
redistribution
[87]. Adiponectin concentrations correlated 
with  body  composition,  insulin  response  to  glucose 
challenge and lipid levels
[87]. Thus adiponectin may be 
a better marker than leptin for insulin resistance seen in 
HIV subjects
[89]. Taking these findings to the molecular 
level  researchers  have  recently  shown  decreased 
adiponectin specific mRNA levels in fat biopsies from 
such lipodystrophic patients
[90].  
  All  the  above  results  support  the  hypothesis  that 
correction  of  adiponectin  levels  may  ameliorate  the 
metabolic changes observed in HIV patients.  
  Uncertainty  exists  with  regards  to  medication 
effects  on  adiponectin  levels  and  is  compounded  by 
their effects on adipogenesis and/or fat loss. Our study 
showed  that  certain  HIV  medications  (NRTIs)  may 
mediate  part  of  hypoadiponectinemia  (eg  through 
peripheral  lipoatrophy)
[82].  A  recent  sudy  reported  an 
association of peripheral lipoatrophy and low levels of 
adiponectin in patients currently or previously treated 
with stavudine
[91]. Among PIs ritonavir has be shown to 
adversely affect adiponectin as well as lipid levels in 
animal  experiments
[86,92].  The  administration  of 
adiponectin  improved  these  changes
[86,92].  It  is  likely 
that  decreased  adiponectin  levels  are  mediated  by  PI 
effects  on  adipogenesis.  Indeed  in  vitro  experiments 
have shown that protease inhibitors inhibit adipogenesis 
in  a  dose  response  manner  in  murine  3T3-L1 
preadipocytes
[93].  However  the  effects  of  individual 
protease  inhibitors  on  adipogenesis  and  adiponectin 
levels may vary from PI to PI similarly to their effects 
on  insulin  resistance  (see  above)  and  may  vary  from 
animal  to  human  experiments.  In  a  recent  effort 
adipokine levels were measured in HIV-negative men 
treated  with  either  indinavir  or  lopinavir/ritonavir
[94]. 
Serum  adiponectin  levels  increased  with  both  agents 
despite their differential effects on insulin sensitivity
[94] 
and  in  contrast  with  the  above  mentioned  in  vitro 
experiments  that  have  showed  decreased  adiponectin 
expression  in  3T3  adipocytes  acutely  treated  with Am. J. Infectious Dis., 2 (3): 141-152, 2006 
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several PIs and NRTIs
[93]. Of  note adiponectin levels 
increased  after  a  few  weeks  of  therapy  suggesting  a 
compensatory response from the adipose tissue through 
a  negative  feedback  mechanism  at  least  at  the  initial 
stages  of  the  metabolic  dysregulation.  Studies 
examining these effects at the human fat cell level have 
looked  at  regional  adipose  cells  obtained  from  HIV 
negative  individuals  treated  with  PIs  and  nucleoside 
analogues.  In  these  experiments  both  PIs  and  NRTIs 
downregulated  adiponectin  expression  from 
subcutaneous adipose tissue cells
[95]. Thus it seems that 
during early phases of antiretroviral therapy adiponectin 
expression is likely downregulated by direct medication 
effects. Later on changes of adipose tissue may lead to 
hypoadiponectinemia  at  later  stages  of  the  metabolic 
syndrome.  Interestingly  in  some  studies  there  is  an 
inverse  relationship  between  adiponectin  and  TNF-
a
[95,96]  raising  the  hypothesis  that  increased  levels  of 
TNF-a -another adipocytokine itself- may contribute to 
the pathogenesis of lipodystrophy
[95,96]. Ritonavir use in 
human adipocyte cell lines was able both to up-regulate 
TNF-a,  IL6  and  leptin  expression  and  down-regulate 
PPAR-g and adiponectin expression
[96] in one of these 
studies. It is well known that in HIV negative subjects 
TNF-￿  suppresses  the  expression  of  transcriptional 
factors  involved  in  adipogenesis  and  lipogenesis 
including  a  downregulation  of  adiponectin  and  IL-
6
[21,97]. Increased TNF- ￿ from abdominal subcutaneous 
adipose tissue as well as elevated circulating levels of 
IL-6, soluble TNF receptors I and II and insulin have 
been observed in HIV patients with fat redistribution
[98-
101].  Moroever  decreased  adiponectin  and  leptin 
expression resulting form increased apoptosis together 
with decreased adipocyte differentiation has been found 
in  experiments  looking  at  adipose  tissue  from  HIV 
subjects  with  peripheral  lipoatrophy  when  compared 
with  samples  from  HIV  negative  controls
[102]  further 
confirming  previous  similar  observations
[103].  These 
leptin  and  adiponectin  changes  likely  mediated  the 
insulin  resistance  found  in  these  subjects
[102].  The 
observed adipocyte changes were partly explained by 
increased levels of TNF-a and interleukin-6 (IL-6)
[102]. 
Obviously it would be interesting to see whether such 
associations  are  observed  in  HIV  patients  examined 
both  at  early  and  later  stages  of  antiretroviral 
therapy
[94].  
  Thus  one  can  formulate  the  hypothesis  that  HIV 
positive  patients  suffering  from  the  HIV  associated 
metabolic  syndrome  suffer  from  a  pre-inflammatory 
state similar to the one seen in the metabolic syndrome 
affecting a large fraction of the general population in 
developed  countries
[104,105].  These  inflammatory 
changes  affect  adiponectin  and/or  leptin  production. 
Recent  work  performed  in  our  lab  has  confirmed  an 
association  of  adiponectin  and  inflammatory  markers 
such  as  CRP  likely  mediated  through  an  underlying 
association  with  obesity  in  diabetic  subjects
[106].  The 
role of inflammatory cytokines in the pathogenesis of 
HIV lipodystrophy is of great interest but is outside the 
scope of the current review. 
  Effects  on  sterol-regulatory-element-binding-
protein-1c (SREBP-1c) a transcription factor involved 
in  the  activation  of  genes  responsible  for  long  chain 
fatty acid synthesis and adipocyte differentiation
[107-109] 
seem to be important in the pathogenesis of the HIV 
metabolic syndrome especially dyslipidemia and body 
shape changes. Experiments with transgenic mice over-
expressing  SREBP-1c  exhibit  a  metabolic  syndrome 
similar to the one seen in HAART treated patients with 
lipoatrophy,  insulin  resistance  and 
hypertriglyceridemia
[110].  Increased  SREBP-1c 
concentration  in  peripheral  adipose  tissue  has  been 
recently associated with decreased expression of PPAR-
￿  and  decreased  adipocyte  differentiation
  in  HIV 
patients  who  developed  lipoatrophy  after  receiving 
HAART-therapy
[111].  Decreased  levels  of  leptin  were 
noted in these patients together with increased TNF-￿
 
suggesting impaired
 adipocyte differentiation and thus 
decreased  adiponectin  levels
[111]  although  adiponectin 
levels were not specifically measured. 
  Decreased adipocyte differentiation or loss, leading 
to  a  decrease  in  adiponectin,  concomitantly  with 
increased  secretion  of  other  inflammatory  cytokines 
(e.g. TNF-a) may in part explain the insulin resistance 
in HIV positive subjects. Some of these effects maybe 
the  result  of  synergistic  actions  by  different  key 
etiopathogenetic  factors.  For  example,  protease 
inhibitors  may  synergistically  act  with  TNF-  ￿  in 
producing antiadipogenic effects
[112]. 
  These  complex  interactions  may  actually  be  the 
result  of  a  fine  balance  between  effects  of  several 
specific antiretrovirals, age, as well as the effect of the 
HIV  illness  itself,  other  concomitant  illnesses  and/or 
genetic  predisposition
[113].  Furthermore,  they  may 
change and evolve depending on other factors such as 
age and environmental stimuli e.g. diet and exercise.  
 
Therapeutic  implications  of  the  adipokine  role: 
Several  strategies  have  been  incorporated  in  clinical 
practice  in  an  attempt  to  handle  the  several 
manifestations of the HIV metabolic syndrome
[1,114-118]. 
We  will  briefly  discuss  thiazolidinedione  effects  and 
their association with adipocytokine changes as well as 
therapy for lipoatrophy with leptin.   
 
Thiazolidinediones  and  their  effects  on  the  HIV 
associated  metabolic  syndrome:  Thiazolidinedione 
are PPAR-￿ agonists that initiate a cascade of events 
leading to transcription or inhibition of genes involved 
in  the  regulation  of  adipocyte  differentiation,  lipid 
metabolism and insulin action
[119-121]. It is well known 
from  in  vitro  experiments  that  PPAR-￿  agonists 
increase adiponectin expression in the adipose tissue
[120] 
and treatment with thiazolidinediones in vivo markedly 
increases circulating adiponectin levels
[122,123]. Am. J. Infectious Dis., 2 (3): 141-152, 2006 
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  One of the first theories to be presented to explain 
the  lipodystrophy  syndrome  was  that  antiretroviral 
medications directly decrease adipocyte differentiation 
by  inhibiting  the  activation  of  nuclear  receptors 
involved  in  adipocyte  differentiation  and  insulin 
induced metabolic changes
[124,125]. This hypothesis has 
been questioned in subsequent studies
[126-128]. If part of 
the theory is correct
[128] we would expect to see some 
beneficial effects of PPAR-￿ therapy in HIV associated 
metabolic  changes.  Moreover  the  physiologic 
associations  observed  in  the  studies  discussed 
previously  would  rationalize  thiazolidinendione 
treatment for some of these changes. 
  Indeed  rosiglitazone  has  been  shown  to  improve 
insulin  resistance  in  patients  with  HIV  associated 
metabolic  syndrome,  however  at  the  expense  of 
increased triglyceride and cholesterol concentrations
[129-
132].  Regarding  fat  redistribution  the  initially 
encouraging  results  reporting  a  beneficial  effect  of 
rosiglitazone  in  body  fat  gain
[129,130]  were  not  seen 
during  two  other  studies  including  a  recent  larger 
(n=108)  placebo  controlled  study
[131]  evaluating 
rosiglitazone  in  lipoatrophic  HIV  patients
[131,132].  This 
has led to the speculation that rosiglitazone may exert 
its  insulin  sensitizing  effects  without  increasing  the 
subcutaneous  adipose  tissue  mass
[132].  Of  note  a 
significant increase in baseline PPAR-g expression in 
adipose  tissue  is  noted  with  rosiglitazone  in  HIV 
positive  subjects
[133].  Thiazolidinediones  may  act 
through  other  mechanisms  as  well.  A  recent  study 
examined gene expression in subcutaneous tissue from 
subjects  with  lipodystrophy  and  showed  significantly 
higher levels of 11-beta hydroxysteroid dehydrogenase 
type-1 in lipodystrophic HIV subjects compared to non 
lipodystrophy cases
[134]. In the liver and adipose tissue 
11 beta hydroxysteroid dehydrogenase type 1 catalyzes 
a  cortisol  forming  reaction  and  transgenic  mice 
overexpressing  this  enzyme  develop  a  full  blown 
metabolic  syndrome  with  obesity  and  increased 
amounts  of  visceral  fat
[135].  Thiazolidinediones 
downregulate  11-beta  hydroxysteroid  dehydrogenase 
type 1 enzyme in adipose tissue and their effect could 
be partially explained by this mechanism
[136].This effect 
is  probably  not  mediated  by  the  action  of  protease 
inhibitors  since  previous  experiments  using  adipose 
stromal cells have shown a dose dependent inhibition of 
this enzyme by saquinavir, indinavir and nelfinavir
[137].  
  Pioglitazone is another thiazolidinedione which has 
a  more  favorable  effect  on  lipid  profile  compared  to 
rosiglitazone
[138,139]. In a recently performed open label 
uncontrolled  study  its  use  in  HIV  patients  was 
associated with adverse effects on insulin resistance and 
an increase in fat mass with no adverse lipid effects
[140]. 
Our group looked at the effects of pioglitazone and/or 
fenofibrate  (a  PPAR-￿  agonist)  in  a  group  of  HIV 
infected  patients  suffering  from  insulin  resistance  or 
diabetes  and/or  hyperlipidemia  in  a  randomized 
controlled  study
[141].  Pioglitazone  administration  over 
12  months  improved  insulin  resistance  and  blood 
pressure  and  affected  the  lipid  profile  favorably  by 
increasing  HDL  levels  in  these  patients
[141].  With 
regards to fat redistribution effects we observed a trend 
towards  an  increase  of  total  body  and  abdominal  fat 
over  the  12  month  pioglitazone  use  by  our  HIV 
subjects
[141]. A significant increase in adiponectin levels 
over  the  study  period  which  was  not  found  in  the 
placebo  group  might  have  mediated  the  beneficial 
effect  in  insulin  resistance  in  our  patients
[141].  These 
effects  could  be  attributed  to  increased  adiponectin 
gene expression which has been reported in association 
with rosiglitazone therapy recently
[133]. Adiponectin and 
PPAR-g expression in adipose tissue has been reported 
to be significantly lower in HIV-infected patients with 
HAART-induced  fat  redistribution
[103].  Other 
mechanisms  could  be  potentially  involved,  such  as  a 
decrease in free fatty acid levels, however pioglitazone 
did  not  significantly  affect  their  concentration  in  our 
study
[141].  Pioglitazone  based  on  its  beneficial  lipid 
effects  seems  a  better  thiazolidinedione  for  the 
treatment of diabetes in HIV-infected subjects. Another 
thiazolidinedione  which  exhibited  similar  effects, 
troglitazone, had to be withdrawn from the market due 
to unacceptable liver toxicity
[142].  
  In conclusion, pioglitazone in preliminary studies 
appears to have a beneficial effect on insulin resistance 
mediated  by  adiponectin  levels  and  favorably  affects 
the  lipid  profile  in  the  HIV  associated  metabolic 
syndrome. Larger studies are necessary to elucidate the 
role of PPAR￿ agonsists alone or in combination with 
other agents i.e. PPAR￿ agonists or recombinant leptin 
in treating HIV related fat redistribution and especially 
lipoatrophy and/or insulin resistance.  
  In  using  thiazolidinediones  one  should  keep  in 
mind  potential  antiretroviral  effects  of  this  class  of 
medications
[143]  which  are  probably  mediated  by 
downregulation  of  TNF-￿  and  IL-6
[144]  which  are 
known  to  promote  HIV  transcription
[144].  More 
importantly  during  thiazolidinedione  therapy  careful 
monitoring  for  important  associated  side  effects  like 
liver toxicity is essential
[119]. 
 
Leptin  therapy  and  the  HIV  associated  metabolic 
syndrome: Recently, leptin administration was used to 
treat  congenital  and  acquired  (non-HIV) 
lipodystrophy
[48].  It  took  four  months  to  achieve 
physiological leptin concentrations in these patients
[48]. 
Leptin  administration  resulted  in  improvement  of 
hyperglycemia,  hyperinsulinemia, 
hypertriglyceridemia, as well as a significant decrease 
in  fatty  infiltration  of  the  liver
[48].  In  light  of  the 
previous discussion and the observed leptin deficiency 
in  patients  with  HIV/HAART-associated 
lipoatrophy
[59],  leptin  administration  alone  or  in 
combination  with  thiazolidinediones  or  switch 
strategies could in theory reverse many of the metabolic 
abnormalities  observed  in  this  syndrome.  Studies  are Am. J. Infectious Dis., 2 (3): 141-152, 2006 
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currently  under  way  and  preliminary  results  are 
encouraging for HIV patients with lipoatrophy and low 
leptin  levels
[145].  Leptin  replacement  therapy  induced 
improvements  in  insulin  resistance  after  2  months  of 
therapy  in  HIV  (+)  lipoatrophic  leptin  deficient 
subjects
[145]. 
 
CONCLUSION 
 
  Multiple  mechanistic  pathways  may  overlap  in 
producing several manifestations of the HIV associated 
metabolic syndrome. Further research may be able to 
elucidate  the  three-fold  association  between  acute 
antiretroviral treatment effects and adiponectin and/or 
leptin  levels  as  well  as  insulin  resistance.  These 
changes  should  be  studied  both  at  early  and  late 
treatment  stages,  in  various  regional  adipose  tissue 
compartments  and  in  the  circulation.  The  predictive 
value of such changes for the subsequent development 
of fat redistribution or other metabolic changes should 
be  estimated  and  the  effect  of  medications  that 
normalize  leptin  and  adiponectin  levels  should  be 
studied. This will further enhance our understanding of 
the complex associations and interrelations between a 
chronic  infection,  toxic  drugs,  genetic  predisposition 
and  environmental  factors  participating  in  generating 
the HIV metabolic syndrome. 
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